XOPENEX
LOE ApproachingNDAINHALATIONSOLUTION
Approved
Mar 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
XOPENEX by Hikma is 2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylate cyclase and to an increase in the intracellular concentration of cyclic-3', 5'-adenosine monophosphate (cyclic amp). First approved in 1999.
Drug data last refreshed 4h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XOPENEX (levalbuterol) is an inhaled short-acting beta-2 adrenergic agonist (SABA) approved in 1999 for acute bronchospasm relief. It works by activating beta-2 receptors on airway smooth muscle, increasing cyclic AMP and triggering muscle relaxation while inhibiting mast cell mediator release. The drug is indicated for patients with reversible obstructive airway disease who require rapid bronchodilation.
$0.005BPart D
LOE ApproachingDeclining
Product is in mature/LOE-approaching phase with minimal Medicare utilization and high generic competitive pressure (30%), indicating small and stabilizing commercial team headcount.
Mechanism of Action
2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylate cyclase and to an increase in the intracellular concentration of cyclic-3', 5'-adenosine monophosphate (cyclic AMP). The increase in cyclic AMP is associated with the activation of protein kinase A, which in turn,…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on XOPENEX at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.